EFMH
CYTK icon

E Fund Management (HK)’s Cytokinetics CYTK Stock Holding History

E Fund Management (HK)’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.2K Buy
319
+80
+33% +$5.74K 0.01% 253
2026
Q1 		$15.8K Buy
+239
New +$15.2K 0.01% 236

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

E Fund Management (HK)'s CYTK Position: Q2 2026 in Review

E Fund Management (HK) increased its Cytokinetics (CYTK) stake by 33% in Q2 2026, buying an estimated $5.74K and bringing the position to 319 shares worth $27.2K. The position accounts for 0.01% of the portfolio, ranked #253.

E Fund Management (HK) first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • E Fund Management (HK) held 319 shares of Cytokinetics worth $27.2K as of Q2 2026.
  • E Fund Management (HK) bought 80 Cytokinetics shares in Q2 2026, an estimated $5.74K.
  • Cytokinetics made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #253 holding.
  • E Fund Management (HK) first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.